AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21778278 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sodium diet (HS, aim 200 mmol Na(+)/day)
Number of subjects: 63
Study 21778278 — intervention group
Group type: COMPARATOR
Intervention: Low-sodium diet (LS, aim 50 mmol Na(+)/day)
Number of subjects: 63
Study 20007734 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone (0.5-1.0 mg before bedtime)
Number of subjects: 31
Study 20007734 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (10-20 mg before bedtime)
Number of subjects: 31
Study 18445635 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin and doxycycline
Number of subjects: 682
Study 15506862 — intervention group
Group type: EXPERIMENTAL
Intervention: More specific feedback
Number of subjects: 0
Study 15506862 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback specificity
Number of subjects: 0
Study 11920267 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fludarabine phosphate on a full stomach
Number of subjects: 18
Study 11920267 — intervention group
Group type: COMPARATOR
Intervention: Oral fludarabine phosphate on a fasted stomach
Number of subjects: 18
Study 9439551 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine infusion
Number of subjects: 8
Study 9439551 — intervention group
Group type: COMPARATOR
Intervention: Arginine infusion
Number of subjects: 8
Study 7947430 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine HCl
Number of subjects: 10
Study 7947430 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% chloroprocaine HCl
Number of subjects: 10
Study 7947430 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% bupivacaine HCl
Number of subjects: 10
Study 7947430 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural catheter insertion
Number of subjects: 10
Study 3661609 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (Carafate) 1 g
Number of subjects: 28
Study 3661609 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (Tagamet) 300 mg
Number of subjects: 28
Study 3661609 — intervention group
Group type: COMPARATOR
Intervention: Placebo 1 g
Number of subjects: 28
Study 30408319 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (PCT)
Number of subjects: 426
Study 30408319 — intervention group
Group type: COMPARATOR
Intervention: Immediate surgery (IS)
Number of subjects: 426
Study 29453671 — intervention group
Group type: EXPERIMENTAL
Intervention: Glaritus® (0.4 IU/kg)
Number of subjects: 40
Study 29453671 — intervention group
Group type: COMPARATOR
Intervention: Lantus® (0.4 IU/kg)
Number of subjects: 40
Study 29453671 — intervention group
Group type: EXPERIMENTAL
Intervention: Glaritus®
Number of subjects: 40
Study 29453671 — intervention group
Group type: COMPARATOR
Intervention: Lantus®
Number of subjects: 40
Study 27672353 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher anxiety sensitivity (AS)
Number of subjects: 136
Study 27672353 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression analysis and longitudinal analysis with multilevel modeling (MLM)
Number of subjects: 136
Study 25113283 — intervention group
Group type: EXPERIMENTAL
Intervention: Zippy's Friends programme
Number of subjects: 766
Study 23037714 — intervention group
Group type: EXPERIMENTAL
Intervention: Toronto criteria
Number of subjects: 2329
Study 23037714 — intervention group
Group type: EXPERIMENTAL
Intervention: PRIAS criteria
Number of subjects: 2329
Study 23037714 — intervention group
Group type: EXPERIMENTAL
Intervention: Cambridge data
Number of subjects: 2329
Study 23037714 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram based on Toronto criteria
Number of subjects: 2329
Study 20053878 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-DHA group (1% DHA)
Number of subjects: 127
Study 20053878 — intervention group
Group type: COMPARATOR
Intervention: Control group (0.3% DHA)
Number of subjects: 127
Study 17628562 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac plus paracervical block
Number of subjects: 113
Study 17628562 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine plus diclofenac
Number of subjects: 113
Study 17628562 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine alone
Number of subjects: 113
Study 16390757 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg
Number of subjects: 383
Study 16390757 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 2.5 mg
Number of subjects: 383
Study 16390757 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 383
Study 11466599 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral treatment (n=46)
Number of subjects: 98
Study 11466599 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic treatment (n=52)
Number of subjects: 98
Study 9236433 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous and oral carvedilol treatment
Number of subjects: 151
Study 9236433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 8433880 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin (IVIG)
Number of subjects: 376
Study 8433880 — intervention group
Group type: COMPARATOR
Intervention: Albumin placebo
Number of subjects: 376
Study 2441593 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 32
Study 2441593 — intervention group
Group type: COMPARATOR
Intervention: Nystatin
Number of subjects: 32
Study 30318090 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-careldopa
Number of subjects: 0
Study 30318090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31693806 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amoxicillin‐clavulanate (1 g and 200 mg, respectively) administered three times a day for 2 days, starting less than 6 hours after cardiac arrest.
Number of subjects: 194
Study 31693806 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered three times a day for 2 days, starting less than 6 hours after cardiac arrest.
Number of subjects: 194
Study 28577545 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (two dietary consultations and access to twice‐weekly exercise groups)
Number of subjects: 606
Study 28577545 — intervention group
Group type: COMPARATOR
Intervention: Control (routine prenatal care)
Number of subjects: 606
Study 25082656 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol 300 mg/day for three months
Number of subjects: 30
Study 25082656 — intervention group
Group type: COMPARATOR
Intervention: Control group (no allopurinol treatment)
Number of subjects: 30
Study 22972448 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone acetonide
Number of subjects: 0
Study 22972448 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care
Number of subjects: 0
Study 21807696 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation (400 mg daily from 18 to 22 weeks' gestation through parturition)
Number of subjects: 849
Study 21807696 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation
Number of subjects: 849
Study 18593746 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial impregnated CVCs
Number of subjects: 118
Study 18593746 — intervention group
Group type: COMPARATOR
Intervention: Standard triple-lumen CVCs
Number of subjects: 118
Study 17014635 — intervention group
Group type: EXPERIMENTAL
Intervention: Face washing twice a day with a standard mild cleanser
Number of subjects: 0
Study 17014635 — intervention group
Group type: EXPERIMENTAL
Intervention: Face washing once a day
Number of subjects: 0
Study 17014635 — intervention group
Group type: EXPERIMENTAL
Intervention: Face washing four times a day
Number of subjects: 0
Study 17014635 — intervention group
Group type: COMPARATOR
Intervention: Face washing twice a day (control group)
Number of subjects: 0
Study 15310641 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 20
Study 15310641 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20
Study 10664923 — intervention group
Group type: EXPERIMENTAL
Intervention: IS‐5‐MN 20 mg immediate release
Number of subjects: 15
Study 10664923 — intervention group
Group type: EXPERIMENTAL
Intervention: IS‐5‐MN 50 mg sustained release
Number of subjects: 15
Study 9297869 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. omeprazole, 40 mg bolus followed by 80 mg/day by continuous infusion for 3 days
Number of subjects: 45
Study 9297869 — intervention group
Group type: COMPARATOR
Intervention: i.v. ranitidine 50 mg i.v. bolus followed by 400 mg/day i.v., continuous infusion for 3 days
Number of subjects: 45
Study 8345983 — intervention group
Group type: EXPERIMENTAL
Intervention: IVGG (400 mg/kg/day for 4 consecutive days)
Number of subjects: 291
Study 8345983 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 291
Study 31505367 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI neurofeedback intervention (Active intervention group)
Number of subjects: 28
Study 31505367 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (Control intervention group)
Number of subjects: 28
Study 30152049 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass drug administration (MDA) of DEC and albendazole
Number of subjects: 627
Study 26801098 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (150 min weekly of combined aerobic and resistance training)
Number of subjects: 137
Study 26801098 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 137
Study 26801098 — intervention group
Group type: COMPARATOR
Intervention: Standard follow-up (Control)
Number of subjects: 137
Study 24999518 — intervention group
Group type: EXPERIMENTAL
Intervention: Mom's Empowerment Program (10-session evidence-based intervention)
Number of subjects: 120
Study 24999518 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no intervention)
Number of subjects: 120
Study 22304620 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentholated cream plus oxygenated glycerol triesters (MC + OGTs)
Number of subjects: 66
Study 22304620 — intervention group
Group type: COMPARATOR
Intervention: Mentholated cream (MC)
Number of subjects: 66
Study 20919804 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbed suture
Number of subjects: 117
Study 20919804 — intervention group
Group type: EXPERIMENTAL
Intervention: Poliglecaprone-25 suture
Number of subjects: 117
Study 20919804 — intervention group
Group type: COMPARATOR
Intervention: Stapler
Number of subjects: 117
Study 18514323 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia patients
Number of subjects: 29
Study 18514323 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia patients with shorter duration of antipsychotic drug exposure
Number of subjects: 29
Study 18514323 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 29
Study 16433076 — intervention group
Group type: EXPERIMENTAL
Intervention: Video information package
Number of subjects: 45
Study 16433076 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 12578787 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescein angiography classification by retinal specialists
Number of subjects: 40
Study 10473837 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to hand‐transmitted vibration
Number of subjects: 107
Study 10473837 — intervention group
Group type: COMPARATOR
Intervention: Control group (31 subjects)
Number of subjects: 107
Study 8740043 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg phenelzine every other day, then 15 mg daily for 6 weeks
Number of subjects: 0
Study 8740043 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 0
Study 1846872 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg conjugated equine estrogen (CEE) + 5 mg medroxyprogesterone acetate (days 15-25)
Number of subjects: 48
Study 1846872 — intervention group
Group type: COMPARATOR
Intervention: 1.25 mg CEE + placebo (days 15-25)
Number of subjects: 48
Study 1846872 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg CEE (days 1-25)
Number of subjects: 48
Study 1846872 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg CEE (days 1-25)
Number of subjects: 48
Study 1846872 — intervention group
Group type: COMPARATOR
Intervention: Placebo (days 15-25)
Number of subjects: 48
Study 6760968 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (20 mg oral dose)
Number of subjects: 10
Study 6760968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31232940 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol (500 mg twice daily 1 day before and 3 days after the operation)
Number of subjects: 220
Study 31232940 — intervention group
Group type: COMPARATOR
Intervention: Control (hydration from 12 hours before to 12 hours after contrast administration)
Number of subjects: 220
Study 31232940 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol
Number of subjects: 220
Study 31232940 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydration
Number of subjects: 220
Study 29209721 — intervention group
Group type: EXPERIMENTAL
Intervention: High-cutoff hemodialysis (46 patients)
Number of subjects: 98
Study 29209721 — intervention group
Group type: COMPARATOR
Intervention: Conventional hemodialysis (48 patients)
Number of subjects: 98
Study 28031304 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based quality assurance (QA) tool for ultrasound exams
Number of subjects: 0
Study 25916131 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous laser therapy (10-day course) using 'matrix-vlok' apparatus, wavelength 0.405 microns, radiation power 1-1.5 mW, continuous mode
Number of subjects: 112
Study 22963759 — intervention group
Group type: EXPERIMENTAL
Intervention: Guillotine technique
Number of subjects: 100
Study 22963759 — intervention group
Group type: COMPARATOR
Intervention: Cold steel dissection
Number of subjects: 100
Study 19229822 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg/day
Number of subjects: 59
Study 19229822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 17497518 — intervention group
Group type: EXPERIMENTAL
Intervention: PARC curriculum
Number of subjects: 9571
Study 17497518 — intervention group
Group type: COMPARATOR
Intervention: Traditional curriculum
Number of subjects: 9571
Study 15149168 — intervention group
Group type: EXPERIMENTAL
Intervention: Melan-A peptide with immune adjuvant AS02B (QS21 and MPL)
Number of subjects: 49
Study 15149168 — intervention group
Group type: EXPERIMENTAL
Intervention: Melan-A peptide in IFA
Number of subjects: 49
Study 11471442 — intervention group
Group type: EXPERIMENTAL
Intervention: Normovolemic hemodilution (NVH) with blood withdrawal of 6-8 ml.kg-1 and intravenous colloid substitution
Number of subjects: 38
Study 11471442 — intervention group
Group type: COMPARATOR
Intervention: Standard transfusion protocol (control group)
Number of subjects: 38
Study 11471442 — intervention group
Group type: EXPERIMENTAL
Intervention: Normovolemic hemodilution (NVH)
Number of subjects: 38
Study 10024217 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk with Lactobacillus GG
Number of subjects: 0
Study 10024217 — intervention group
Group type: COMPARATOR
Intervention: Milk (without Lactobacillus GG)
Number of subjects: 0
Study 7865434 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 250 mg/m2 i.v. over 24 hours every 3 weeks
Number of subjects: 52
Study 7865434 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 200 to 250 mg/m2 i.v. over 24 hours every 3 weeks
Number of subjects: 52
Study 7865434 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin/etoposide chemotherapy (standard)
Number of subjects: 52
Study 7865434 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 135 mg/m2 i.v. over 24 hours plus cisplatin 75 mg/m2 i.v.
Number of subjects: 52
Study 7865434 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 250 mg/m2 i.v. over 24 hours plus cisplatin 75 mg/m2 i.v. plus recombinant human granulocyte colony-stimulating factor
Number of subjects: 52
Study 2494240 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin, 10 or 20 cm2 (5 or 10 mg/24 h) (Group A)
Number of subjects: 206
Study 2494240 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin, 30 or 40 cm2 (15 or 20 mg/24 h) (Group B)
Number of subjects: 206
Study 2494240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study 31537025 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg/day)
Number of subjects: 134
Study 31537025 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort (30 mg/day)
Number of subjects: 134
Study 31537025 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (Tamsulosin and Deflazacort)
Number of subjects: 134
Study 31537025 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol on demand (Control group)
Number of subjects: 134
Study 31563255 — intervention group
Group type: EXPERIMENTAL
Intervention: Community pharmacist-led intervention
Number of subjects: 684
Study 31563255 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 684
Study 29208688 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval-walking (IW; repeated cycles of 3 min slow [54% of VO2peak] and 3 min fast walking [89% of VO2peak])
Number of subjects: 13
Study 29208688 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous walking (CW; intended 73% of VO2peak)
Number of subjects: 13
Study 29208688 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 13
Study 25062611 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus subtilis R0179 at 0.1×10^9 cfu/capsule/day
Number of subjects: 81
Study 25062611 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus subtilis R0179 at 1.0×10^9 cfu/capsule/day
Number of subjects: 81
Study 25062611 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus subtilis R0179 at 10×10^9 cfu/capsule/day
Number of subjects: 81
Study 25062611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 24382526 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic powder
Number of subjects: 47
Study 24382526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 21282540 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) 100 mg/d
Number of subjects: 667
Study 21282540 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (WAR) 1.25 mg/d
Number of subjects: 667
Study 21282540 — intervention group
Group type: COMPARATOR
Intervention: Low molecular weight heparin (LMWH) - Enoxaparin 40 mg/d
Number of subjects: 667
Study 18164303 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin (3.6 mg subcutaneous depot every 4 weeks for 3 doses)
Number of subjects: 66
Study 18164303 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide (3.75 mg subcutaneous depot every 4 weeks for 3 doses)
Number of subjects: 66
Study 16474028 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifapentine 900 mg/isoniazid 900 mg once weekly for 12 weeks
Number of subjects: 399
Study 16474028 — intervention group
Group type: COMPARATOR
Intervention: Rifampin 450-600 mg/pyrazinamide 750-1,500 mg daily for 8 weeks
Number of subjects: 399
Study 16474028 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifapentine/isoniazid
Number of subjects: 399
Study 16474028 — intervention group
Group type: COMPARATOR
Intervention: Rifampin/pyrazinamide
Number of subjects: 399
Study 14563581 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary thrombectomy followed by stenting
Number of subjects: 92
Study 14563581 — intervention group
Group type: COMPARATOR
Intervention: Conventional strategy of stenting
Number of subjects: 92
Study 11028466 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetics
Number of subjects: 900
Study 11028466 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetics
Number of subjects: 900
Study 8864797 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate 250 mg retard capsules
Number of subjects: 20
Study 8864797 — intervention group
Group type: COMPARATOR
Intervention: Lipanthyl 250 mg retard capsules
Number of subjects: 20
Study 1617931 — intervention group
Group type: EXPERIMENTAL
Intervention: roxithromycin (150 mg b.i.d.)
Number of subjects: 96
Study 1617931 — intervention group
Group type: COMPARATOR
Intervention: amoxicillin‐clavulanic acid (500 mg/125 mg t.i.d.)
Number of subjects: 96
Study 6366550 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with fluorouracil and semustine
Number of subjects: 621
Study 6366550 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with methanol extraction residue of BCG
Number of subjects: 621
Study 6366550 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with fluorouracil, semustine, and immunotherapy
Number of subjects: 621
Study 6366550 — intervention group
Group type: COMPARATOR
Intervention: Close follow-up without adjuvant treatment
Number of subjects: 621
Study 29891538 — intervention group
Group type: EXPERIMENTAL
Intervention: NY-ESO-1c259T cells (autologous T cells expressing NY‐ESO‐1c259)
Number of subjects: 12
Study 27393505 — intervention group
Group type: EXPERIMENTAL
Intervention: para-toluenesulfonamide (PTS) intratumoral injection
Number of subjects: 90
Study 25694460 — intervention group
Group type: EXPERIMENTAL
Intervention: $10 Tim Hortons gift card
Number of subjects: 534
Study 25694460 — intervention group
Group type: COMPARATOR
Intervention: Control group (no incentive)
Number of subjects: 534
Study 22808940 — intervention group
Group type: EXPERIMENTAL
Intervention: Holistic yoga program (1 hour/day, for 12 weeks)
Number of subjects: 90
Study 22808940 — intervention group
Group type: COMPARATOR
Intervention: Physical exercise (1 hour/day, for 12 weeks)
Number of subjects: 90
Study 20942940 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo) 40,000 IU weekly infusions for 8 weeks
Number of subjects: 80
Study 20942940 — intervention group
Group type: COMPARATOR
Intervention: Saline (NaCl 0.9%) weekly infusions for 8 weeks
Number of subjects: 80
Study 18263856 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocapnic hypoxia (IH)
Number of subjects: 10
Study 18263856 — intervention group
Group type: EXPERIMENTAL
Intervention: Poikilocapnic hypoxia (PH)
Number of subjects: 10
Study 16803917 — intervention group
Group type: EXPERIMENTAL
Intervention: Subarachnoid block (SAB) with bupivacaine, clonidine, and morphine
Number of subjects: 89
Study 16803917 — intervention group
Group type: EXPERIMENTAL
Intervention: Subarachnoid block (SAB)
Number of subjects: 89